Zoetis Inc. vs Middle East Pharmaceutical Industries Company
A head-to-head of Zoetis Inc. (ZTS) and Middle East Pharmaceutical Industries Company (4016) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | ZTS | 4016 |
|---|---|---|
| Market Cap | $32.10B | 2.06B SAR |
| P/E (TTM) | 12.70 | 12.46 |
| Forward P/E | 10.36 | 11.57 |
| P/S | 3.64 | 4.19 |
| P/B | 11.89 | 5.07 |
| EV/EBITDA | 10.32 | 9.59 |
| Dividend Yield | 2.31% | 2.39% |
| Profit Margin | 27.79% | 21.19% |
| Gross Margin | 71.84% | 62.29% |
| Operating Margin | 38.00% | 23.74% |
| Revenue Growth (YoY) | +2.91% | +33.65% |
| FCF Yield | 6.44% | 1.62% |
| Debt / Equity | 279.77 | 19.87 |
| Current Ratio | 3.15 | 2.85 |
Which is better: Zoetis Inc. or Middle East Pharmaceutical Industries Company?
- ✓Larger by market cap: Zoetis Inc.
- ✓Cheaper valuation (lower P/E): Middle East Pharmaceutical Industries Company
- ✓Higher dividend yield: Middle East Pharmaceutical Industries Company
- ✓More profitable (net margin): Zoetis Inc.
- ✓Faster revenue growth: Middle East Pharmaceutical Industries Company
- ✓Higher free-cash-flow yield: Zoetis Inc.
Across 13 available metrics, Zoetis Inc. leads 7–6.
There's no single "better" — it depends on your goal: income investors may prefer the higher yield, growth investors the faster grower, and value investors the cheaper one. See each stock's page for deeper detail. This is an automated read, not a recommendation.
Share:
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.